Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Short Title: S2408

Enrollment Status: Active, not recruiting

NCT #: NCT06807437

Specialty Area: Oncology

Conditions Studied: Pancreatic Cancer; Pancreatic Neoplasm; Pancreatic Pre-Cancerous Lesions

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To determine whether giving lanreotide before surgery reduces the risk of developing a postoperative pancreatic fistula (POPF) in patients undergoing distal pancreatectomy for pancreatic cancer or pre-cancerous lesions.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Undergoing distal pancreatectomy for pancreatic cancer or a lesion that could become cancerous
No contraindications to lanreotide
Eligible for surgery with curative intent
Adequate organ function and performance status

What's Involved

Participation in the study will include:

A single injection of lanreotide or placebo before surgery
Distal pancreatectomy (surgical removal of part of the pancreas)
Monitoring for surgical complications, especially pancreatic fistula
Blood collection
Questionnaires about symptoms and recovery

Principal Investigator

Alicia Gingrich, MD

Surgical Oncology

A Member of

(775) 982–6270

Renown Surgery Care

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06807437

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews